NASA NTRS · 20210000516
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Russell Valentine, Rachael Miller, Kimesha Calaway, Gail Perusek. HemoCue ISS Technology Demonstration. https://ntrs.nasa.gov/citations/20210000516
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The Exploration Laboratory Analysis (ELA) project supports the Exploration Medical Capability Element under the NASA Human Research Program. ELA instrumentation is identified as an essential capability for future exploration missions to diagnose and treat evidence-based medical conditions. However, mission architecture limits the medical equipment, consumables, and procedures that will be available to treat medical conditions during human exploration missions. Allocated resources such as mass, power, volume, and crew time must be used efficiently to optimize the delivery of in-flight medical care. Although commercial instruments can provide the blood and urine based measurements required for exploration missions, these commercial-off-the-shelf devices are prohibitive for deployment in the space environment. The objective of the ELA project is to close the technology gap of current minimally invasive laboratory capabilities and analytical measurements in a manner that the mission architecture constraints impose on exploration missions. Besides micro gravity and radiation tolerances, other principal issues that generally fail to meet NASA requirements include excessive mass, volume, power and consumables, and nominal reagent shelf-life. Though manned exploration missions will not occur for nearly a decade, NASA has already taken strides towards meeting the development of ELA medical diagnostics by developing mission requirements and concepts of operations that are coupled with strategic investments and partnerships towards meeting these challenges. This paper focuses on the remote environment, its challenges, biomedical diagnostics requirements and candidate technologies that may lead to successful blood-urine chemistry and biomolecular measurements in future space exploration missions.
A multilateral, web-based symposium, featuring ISS Increment 66 investigations will be held on December 14, 15 and 16, 2021 beginning at 0600 CST each day. The purpose of this event is for Principal Investigators to present their science objectives, testing approach, and measurement methods to agency scientists, managers, and other investigators. Participation is encouraged to gather a global picture of the science planned to be performed on ISS during Increment 66. Please note that only Increment 66 new investigations and those that have not been covered by previous science symposia will be included. We will be in touch with the investigations’ POCs to confirm the presentations and identify the speakers as we develop the preliminary agenda for the Symposium. The agenda and additional details will be distributed prior to the symposium. Presentations will be organized by discipline and will be allotted 15 minutes to highlight the main contributions of their experiment. There will be a short question and answer period after each discipline group session is complete. Please include back-up material as needed. The presentations may be made available to ISS crew members as review material for on-orbit science preparation and/or public outreach activities. Therefore, please ensure a comprehensive presentation (additional back-up material may be provided). The presentations should briefly cover the following: - Science background and hypothesis - Investigation goals and objectives - Measurement approach - Importance and reason for ISS - Expected results and how they will advance the field - Earth benefits/spin-off applications Please note that all presentations and discussions should be limited to content approved for export and information that can be shared with participants and the general public.